Matrine, an active component of root extracts from Sophora flavescens Ait, is the main chemical ingredient of Fufang Kushen injection which was approved by Chinese FDA (CFDA) in 1995 as an anticancer drug to treat non-small cell lung cancer and liver cancer in combination with other anticancer drugs. Owning to its druggable potential, matrine is considered as an ideal lead compound for modification. We delineate herein the synthesis and anticancer effects of 17 matrine derivatives bearing benzo-α-pyrone structures. The results of cell viability assays indicated that most of the target compounds showed improved anticancer effects. Further studies showed that compound 5i could potently inhibit lung cancer cell proliferation in vitro and in vivo with no obvious side effects. Moreover, compound 5i could induce G1 cell cycle arrest and autophagy in lung cancer cells through up-regulating P27, down-regulating CDK4 and cyclinD1 and attenuating PI3K/Akt/mTOR pathway. Suppression of autophagy attenuated 5i induced proliferation inhibition. Collectively, our results infer that matrine derivative 5i bears therapeutic potentials for lung cancer.
1
. Currently, chemotherapy is the main treatment of lung cancer 2 . Although the survival of lung cancer patients has been improved with the emergence of tyrosine kinase inhibitors 3, 4 , there still comes with new issues, such as drug resistance. It is of significant need to develop novel drugs to improve lung cancer patient outcomes.
Matrine, extracted from roots of Sophora Flavescens Ait is the main chemical ingredient of Fufang Kushen injection which was approved by Chinese FDA (CFDA) in 1995 as an anticancer drug to treat non-small cell lung cancer and liver cancer in combination with other anticancer drugs [5] [6] [7] [8] [9] [10] . Recently, considerable literatures have reported that matrine has promising anticancer activity 11 . Besides, due to its druggable advantages, such as flexibility structure and good safety profiles, matrine is considered as an ideal lead compound for further modification [12] [13] [14] [15] . In our previous study 16 , 19 matrine derivatives were synthesized and derivative 6i showed the strongest anticancer effects towards A549 lung cancer cells in vitro. However, 6i displayed obvious toxicity in the in vivo mouse model. In the present study, in order to obtain compounds with potent anticancer effects and low toxicity, we used matrine as a lead compound to synthesize 17 matrine derivatives bearing benzo-α -pyrone structures which are a group of compounds including flavonoids and coumarins and could improve the pharmacological activity of compounds 17 . Further, the anticancer effects of these 17 matrine derivatives were screened and the anticancer mechanism of compound 5i was investigated.
Results
Cytotoxic activities of matrine derivatives. The synthetic route for benzo-α -pyrone matrine derivatives is outlined in Fig. 1 and depicted in Methods and supplementary information. All the available derivatives were evaluated for their cytotoxic activities against four human cancer cell lines, including A549 (lung cancer cell), MCF-7 (breast cancer cell), SGC-7901 (gastric cancer cell) and Bel-7402 (hepatocellular cancer cell) ( Table 1) . Most of the derivatives exhibited improved anticancer efficacies with IC 50 15~484 times lower than that of matrine. Compound 5c, 5f, 5g and 5i showed better anticancer effects than other matrine derivatives. The anticancer effectiveness of the original matrine compound and these four derivative compounds were ordered as follows: 5i > 5c > 5g ≈ 5f > > matrine. Compounds 5c and 5i have the same substituent group 6′ ,8′ -di-tert-butyl in benzo-α -pyrone structure. Compound 5i is the N-oxidation product of 5c. It suggested that the substituent group 6′ ,8′ -di-tert-butyl in benzo-α -pyrone structure and N-oxidation could both improve anticancer effects. It also can be found that 6′ ,8′ -di-tert-butyl group showed better anticancer effects than 6′ -bromo or 6′ -chloro group in benzo-α -pyrone structure. Considering the favorable cytotoxic activities of compound 5i and lung cancer morbidity and mortality, we chose compound 5i as the representative compound for further investigation on lung cancer model.
Compound 5i inhibits lung cancer cell proliferation and colony formation. To detect whether 5i treatment could inhibit cell growth in lung cancer cells, cell viability assays were performed in lung cancer cells (Fig. S1) . H1975, H460, and A549 were the most sensitive cell lines to compound 5i. Furthermore, the results showed that 5i potently inhibited cell growth in a time-and dose-dependent manner in the tested cell lines (Fig. 2a, Fig. S2a ). The IC 50 at 48 hours for A549, H460, and H1975 was found around 8, 6, and 5 μ M, respectively. Therefore, we used 4 μ M (around IC 20 ) of 5i in the following studies. The colony formation results demonstrated that 5i significantly inhibited lung cancer cell colony forming activity (Fig. 2b, Fig. S2b ).
Compound 5i induces G1 cell cycle arrest in lung cancer cells. To further define the anticancer effects of 5i on lung cancer cells, we conducted cell cycle analysis in A549, H460, and H1975 cells. Cells were treated with different concentrations of 5i for 24 hours. The results displayed that 5i arrested cell cycle of H460 and A549 at G1 phase in a dose-dependent manner (Fig. 2c) . The percentage of G1 phase in H460 cells increased from 43% (control) to 57% (4 μ M, p = 0.04) and 64% (6 μ M, p = 0.01), respectively (Fig. 2c, left) . Consistently, the percentage of G1 phase in A549 cells increased from 49% (control) to 63% (4 μ M, p = 0.02) and 68% (6 μ M, p = 0.01), respectively ( Fig. 2c, right) . However, 5i could not induce G1 cell cycle arrest in H1975 cells (Fig. S2c) . To dissect the underlying mechanism of compound 5i induced G1 cell cycle arrest, we conducted western blot assays. The results revealed that upon 5i treatment, CDK4 and CyclinD1 were down-regulated, while P27 was up-regulated in both H460 and A549 cells (Fig. 2d ).
Compound 5i induces autophagy and attenuates PI3K/AKT/mTOR pathway in lung cancer cells. Autophagy is a lysosome-mediated process involved in protein and organelle degradation 18 . Autophagy could suppress tumor progression through limiting genome instability, restricting inflammation and promoting tumor cell apoptosis 19 . To test whether compound 5i could induce autophagy, H460, A549, and H1975 cells were treated with 5i for 24 hours. The immunofluorescence results exhibited that LC3, an autophagy indicator was activated in both H460 and A549 lung cancer cells (Fig. 3a) . LC3 activation was also confirmed by western blotting assays results (Fig. 3b) . While in H1975 cells, 5i could not induce autophagy (Fig. S2d, S2e ).
The process of autophagy is well-regulated and PI3K/AKT/mTOR pathway plays a key role in this process 18, 20 . To further dissect the underlying molecular mechanism of compound 5i induced autophagy, we detected the activity of PI3K/AKT/mTOR pathway in H460, A549, and H1975 lung cancer cells upon 5i treatment. The results showed that with treatment of compound 5i, the PI3K/AKT/mTOR pathway was down-regulated in both H460 and A549 lung cancer cells in a dose-dependent manner (Fig. 3c ), but not in H1975 lung cancer cells (Fig. S2e) .
Suppression of autophagy attenuates compound 5i induced cell viability inhibition and G1 cell cycle arrest. To unveil the role of autophagy in 5i induced cell viability inhibition, we alleviated autophagy induced by 5i by using autophagy inhibitor 3-MA and evaluated the cell viabilities in H460 and A549 cells. The results showed that with co-treatment of 5i and 3-MA, 5i induced autophagy was attenuated by 3-MA reflected by immunofluorescence (Fig. 4a ) and western blotting results (Fig. 4b) . Moreover, the results of MTT assays showed that the cell viability inhibition of 5i was also attenuated by 3-MA in both H460 and A549 lung cancer cells (Fig. 4c) . Further investigations on the G1 cell cycle indicated that co-treatment of 5i with 3-MA significantly alleviated the G1 cell cycle arrest in both H460 and A549 lung cancer cells (Fig. 4d) .
In vivo anti-lung cancer activity of compound 5i. To evaluate the anti-lung cancer activity of compound 5i in vivo, A549-luciferase cells (1 × 10 6 ) were intravenously injected into SCID/Beige mice (n = 6 for each group). Vehicle, 5i (10, 20 mg/kg), and matrine (20 mg/kg) were intraperitoneally administrated every other days for 3 weeks. The results demonstrated that 5i significantly suppressed tumor growth reflected by decrease of luciferase bioluminescence intensity, while matrine had no obvious effect (Fig. 5a,b) . Besides, 5i treatments did not lead to body weight reduction (Fig. 5c ). Tumor can be obviously found in the dissected lung tissue of vehicle and matrine group, while in 5i group, tumor size decreased dramatically in a dose-dependent manner (Fig. 5d) . Consistent with the results in Fig. 5a,d , 5i reduced dissemination of disease and prevented destruction of tissue architectures reflected by HE staining (Fig. 5e) . We also tested the adverse effects of 5i. The results demonstrated that mice treated with 5i had normal serum concentration of Alanine Aminotransferase (ALT), creatinine (Cr), and Aspartate aminotransferase (AST) compared with vehicle control (Fig. 5f-h ). These results inferred that 5i displayed favorable anti-tumor effect in vivo with no obvious side effects. 
Discussion
Matrine is a highly polar basic compound and used in the treatment of hepatitis and hepatic fibrosis in China for a long time with low toxicity 21 . Recently, the anticancer effects of matrine have become attractive for its broad anticancer spectrum and good safety [22] [23] [24] . Besides, clinical studies have demonstrated that the quality of life and immune function of cancer patients were largely improved by combining standard therapies with the use of matrine 25, 26 . However, the low bioavailability of matrine has limited its use as an anticancer drug. In virtue of its favorable safety and low bioactivity, we designed and synthesized 17 matrine derivatives bearing benzo-α -pyrone structure which appears as a core skeleton in many anticancer compounds 17 . The results of in vitro cytotoxic activity assays indicated that most of the target compounds showed improved anticancer effects with IC 50 15~484 times lower than that of matrine in four tested human cancer cell lines (Table 1) . Compound 5i exhibited the most potent anticancer effects. Moreover, compound 5i inhibited lung cancer cell proliferation in vitro and in vivo (Fig. 2a, Fig. S2a , and Fig. 5a,b) . Interestingly, in our previous study, we discovered that matrine derivative 6i bearing p-methoxyphenyl structure also showed strong anticancer effect in A549 lung cancer cell lines (IC 50 = 1.6 μ M), but displayed toxicity in the in vivo mouse model. Compared with 6i, compound 5i of this study displayed no obvious side effects reflected by body weight loss and ALT, AST and Cr detection (Fig. 5c,f-h ). These results implied that compound 5i displayed advantage in drug safety and druggable potential. Epidermal growth factor receptor (EGFR) mutation plays an oncogenic role in lung cancer initiation 27 . Lung cancer patients with EGFR mutation accounts for 10% of non-small cell lung cancer (NSCLC) in United States and about 40% of NSCLC in East Asia 4, 28 . Thus, tyrosine kinase inhibitors (TKIs) specific for EGFR (EGFR-TKIs) have become a main focus in lung cancer therapy. The efficiency of first-generation EGFR-TKIs, such as gefitinib, could reach 70-80% in NSCLC patients harboring EGFR mutations (exon 19 deletion and L858R) 4, 29 . However, patients gradually develop acquired resistance to EGFR-TKIs within 12 months. The most common mechanism of resistance is a second mutation of EGFR (T790M), which accounts for 50% of all resistances cases and results in the continued activation of PI3K/AKT pathway 30 . Thus, the therapeutic strategies for lung cancer patients with EGFR wild type, first mutation, or acquired mutation could be different. In this study, we discovered that compound 5i could not only inhibit the proliferation of A549 and H460 lung cancer cells (EGFR wild type) but also H1975 lung cancer cells (EGFR acquired mutation, L858R and T790M mutation) (Fig. 2a, Fig. S2a ). However, compound 5i could induce G1 cell cycle arrest and autophagy and attenuate PI3K/AKT pathway in A549 and H460 lung cancer cells (Fig. 2c, Fig. 3 ) but not in H1975 lung cancer cells (Fig. S2c-e) . The anti-proliferative activity mechanism of 5i on EGFR wild type lung cancer cells and EGFR double mutation lung cancer cells might be different. Thus, the anti-proliferative effects mechanism of 5i on H1975 lung cancer cells needs further investigated.
Autophagy is a cellular process whereby the cell degrades subcellular materials to generate energy. To our best knowledge, autophagy plays a paradoxical role in cancer development 18 . Inactivation of autophagy-specific genes (beclin1, atg5) resulted in increased tumorigenesis while activation of autophagy may help cancer cells survive in nutrient-limited environments. Therefore, it is important to distinguish between cytoprotective and cytotoxic autophagy. In this study, we found that compound 5i could induce autophagy in lung cancer cells (Fig. 3) . Moreover, suppression of autophagy with 3-MA attenuated 5i induced cell viability inhibition (Fig. 4c) . These results indicated that autophagy played a cytotoxic role in compound 5i induced lung cancer cell viability inhibition. PI3K/Akt pathway is abnormally activated in many malignancies (such as gastric, breast and hepatic cancer), which could turn autophagy off 20 . Also, PI3K/Akt pathway plays a vital role in cancer cell proliferation. In this study, we discovered that compound 5i could dramatically down-regulated PI3K/Akt pathway. Considering abnormal activities of PI3K/Akt pathway in cancer and the inhibition effects of 5i on PI3K/Akt pathway, we could infer that 5i exhibited its pan anticancer effects by inhibiting PI3K/Akt pathway activities.
In conclusion, we synthesized 17 matrine derivatives which showed improved anticancer activities towards cancer cell lines. Compound 5i displayed the strongest anticancer activity which inhibited lung cancer cell proliferation in vitro and in vivo with no obvious side effects. Further studies indicated that compound 5i arrested cell cycle at G1 phase and induced autophagy in lung cancer cells. Moreover, compound 5i could down-regulate PI3K/Akt pathway and suppression of autophagy attenuated 5i induced proliferation inhibition. Our studies suggested that matrine derivative 5i could be a potential effective compound to treat lung cancer.
Methods
General procedure of matrine derivatives synthesis. 32 . In this step, 4-hydroxy salicylaldehyde was selectively protected by methoxymethyl ether 33 . Products 5a~h were prepared via intramolecular aldol reaction with 1,8-diazabicyclo [5.4 .0]undec-7-ene (DBU) in refluxing anhydrous toluene 34 . In view of natural prevalently occurring N-oxidation in quinolizidine alkaloid, derivatives 5i~k were synthesized by converting products 5c~e to their N-oxide forms with 3-chloroperbenzoic acid (m-CPBA) in ice-cold chloroform. Derivatives 5l~q were produced by removing the N-Boc structure from their corresponding products 5 in hydrochloric acid methanol solution rather than trifluoroacetic acid/dichloromethane concerning to the lactone stability. Under this acidic condition, the protection group methoxymethyl ether of 5d was dropped off along with N-Boc, giving the corresponding phenolic compound.
All reagents and solvents were purchased from commercial sources. Further purification and drying by standard methods were employed when necessary. For thin layer chromatography (TLC) analysis Qingdao haiyang GF254 silica gel plates were used. Column chromatography was carried out using Qingdao haiyang 300-400 mesh silica gel. All NMR spectra were recorded on Bruker AVANCE 600 spectrometers operating at 1 H and 13 C frequencies of 600.17 and 150.91 MHz, respectively, using DMSO-d 6 
